These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15853431)

  • 21. Reducing the risk of meningitis among incoming freshmen.
    FDA Consum; 2001; 35(5):4-5. PubMed ID: 11697094
    [No Abstract]   [Full Text] [Related]  

  • 22. Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research.
    Getsios D; Caro I; El-Hadi W; Caro JJ
    Int J Technol Assess Health Care; 2004; 20(3):280-8. PubMed ID: 15446757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neisseria meningitidis serogroup A vaccines: an overview.
    Vergnano S; Heath P
    Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward a meningitis-free world.
    Black S; Pizza M; Nissum M; Rappuoli R
    Sci Transl Med; 2012 Feb; 4(123):123ps5. PubMed ID: 22378923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New meningococcal A vaccine is being introduced into Africa.
    Mayor S
    BMJ; 2010 Nov; 341():c6736. PubMed ID: 21106620
    [No Abstract]   [Full Text] [Related]  

  • 26. Winter is coming: vaccine negotiations should be concluded swiftly.
    Glennie L; Wright C; Head C
    BMJ; 2014 Nov; 349():g6748. PubMed ID: 25394501
    [No Abstract]   [Full Text] [Related]  

  • 27. Vaccine shortage threatens spread of meningitis in Niger.
    Maurice J
    Lancet; 2015 Jun; 385(9984):2241. PubMed ID: 26088485
    [No Abstract]   [Full Text] [Related]  

  • 28. Modeling the cost-effectiveness of the integrated disease surveillance and response (IDSR) system: meningitis in Burkina Faso.
    Somda ZC; Perry HN; Messonnier NR; Djingarey MH; Ki SO; Meltzer MI
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20927386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statement on meningococcal vaccination for travellers. An Advisory Committee Statement (ACS).
    Committee to Advise on Tropical Medicine (CATMAT)
    Can Commun Dis Rep; 2009 Jun; 35(ACS-4):1-22. PubMed ID: 19526652
    [No Abstract]   [Full Text] [Related]  

  • 30. Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis.
    Pérez-Trallero E; Vicente D; Montes M; Cisterna R
    Lancet; 2002 Sep; 360(9337):953. PubMed ID: 12354504
    [No Abstract]   [Full Text] [Related]  

  • 31. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
    LaForce FM; Okwo-Bele JM
    Health Aff (Millwood); 2011 Jun; 30(6):1049-57. PubMed ID: 21653956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new conjugate meningococcal vaccine (Menveo).
    Med Lett Drugs Ther; 2010 Jul; 52(1343):59-60. PubMed ID: 20651639
    [No Abstract]   [Full Text] [Related]  

  • 33. Meningococcal vaccine use in college students.
    Kelleher JA; Raebel MA
    Ann Pharmacother; 2002 Nov; 36(11):1776-84. PubMed ID: 12398576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine offers meningitis hope.
    Butler D
    Nature; 2010 Nov; 468(7321):143. PubMed ID: 21068797
    [No Abstract]   [Full Text] [Related]  

  • 35. Authors' reply to Rappuoli and colleagues, Black, and Glennie and colleagues.
    Christensen H; Trotter CL; Hickman M; Edmunds WJ
    BMJ; 2014 Nov; 349():g6758. PubMed ID: 25394639
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.
    Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG
    PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacterial meningitis. Appeal to thwart deadly outbreak.
    Vogel G
    Science; 2002 Oct; 298(5592):339. PubMed ID: 12376673
    [No Abstract]   [Full Text] [Related]  

  • 38. Contributions of the Norwegian Institute of Public Health to the development of vaccines against serogroup B meningococcal disease.
    Rosenqvist E; Holst J; Nøkleby H
    Vaccine; 2007 Jan; 25(6):965-6. PubMed ID: 17052822
    [No Abstract]   [Full Text] [Related]  

  • 39. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad.
    Lydon P; Zipursky S; Tevi-Benissan C; Djingarey MH; Gbedonou P; Youssouf BO; Zaffran M
    Bull World Health Organ; 2014 Feb; 92(2):86-92. PubMed ID: 24623901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teenagers in England to be vaccinated against meningitis group W.
    Wise J
    BMJ; 2015 Mar; 350():h1486. PubMed ID: 25779377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.